
CLAIMS

1. Use of a pharmaceutical composition comprising a cyclodextrin and a compound of formula (F-I) or a pharmaceutically acceptable salt thereof:




F-I

in the manufacture of a medicament for the treatment of acute respiratory distress syndrome (ARDS) in a patient in need thereof, wherein a therapeutically effective amount of the pharmaceutical composition is to be administered to the patient.

2. The use of claim 1, wherein a total dosage of the compound of formula (F-I) or the pharmaceutically acceptable salt thereof to be administered per administration is about 50 mg, 100 mg, 150 mg, 200 mg, 300 mg, 400 mg, or 500 mg, or any dosage in between.

3. The use of claim 1 or 2, wherein the pharmaceutical composition is to be administered once or twice per day.

4. Use of a pharmaceutical composition comprising a cyclodextrin and a compound of formula (F-I) or a pharmaceutically acceptable salt thereof:




F-I

in the manufacture of a medicament for the treatment of acute respiratory distress syndrome (ARDS) in a patient with COVID-19, wherein a therapeutically effective amount of the pharmaceutical composition is to be administered to the patient.

5. The use of claim 4, wherein a total dosage of the compound of formula (F-I) or the pharmaceutically acceptable salt thereof to be administered per administration is about 50 mg, 100 mg, 150 mg, 200 mg, 300 mg, 400 mg, or 500 mg, or any dosage in between.

6. The use of claim 4 or 5, wherein the pharmaceutical composition is to be administered once or twice per day.

7. Use of a compound of formula (F-I) or a pharmaceutically acceptable salt thereof:




F-I

in the manufacture of a medicament for the treatment of acute respiratory distress syndrome (ARDS) in a patient in need thereof.

8. The use of claim 7, wherein a total dosage of the compound of formula (F-I) or the pharmaceutically acceptable salt thereof to be administered per administration is about 50 mg, 100 mg, 150 mg, 200 mg, 300 mg, 400 mg, or 500 mg, or any dosage in between.

9. The use of claim 7 or 8, wherein the compound of formula (F-I) or the pharmaceutically acceptable salt thereof is to be administered once or twice per day.

10. Use of a compound of formula (F-I) or a pharmaceutically acceptable salt thereof:



F-I

in the manufacture of a medicament for the treatment of acute respiratory distress syndrome (ARDS) in a patient with COVID-19.

11. The use of claim 10, wherein a total dosage of the compound of formula (F-I) or the pharmaceutically acceptable salt thereof to be administered per administration is about 50 mg, 100 mg, 150 mg, 200 mg, 300 mg, 400 mg, or 500 mg, or any dosage in between.

12. The use of claim 10 or 11, wherein the compound of formula (F-I) or the pharmaceutically acceptable salt thereof is to be administered once or twice per day.